Henkel
This article was originally published in The Rose Sheet
Executive Summary
Completion of the Dial purchase will result in an "immediate increase" in Henkel's operating profit, Dusseldorf, Germany firm announces during annual general meeting April 19. Henkel previously estimated the acquisition would add $1.48 bil. (€1=$1.23) to net revenue. "With Dial having generated sales of €1.2 bil. in fiscal 2003, the structure of Henkel group is bound to undergo significant changes both in terms of product portfolio and regional weighting," President and CEO Ulrich Lehner added. Dial shareholders approved the $2.9 bil. acquisition in March (1"The Rose Sheet" March 29, 2004, In Brief). Henkel said future Dial R&D will focus on products that address the "biologically active" portion of hair...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.